Cargando…
Target Modulation by a Kinase Inhibitor Engineered to Induce a Tandem Blockade of the Epidermal Growth Factor Receptor (EGFR) and c-Src: The Concept of Type III Combi-Targeting
Cancer cells are characterized by a complex network of interrelated and compensatory signaling driven by multiple kinases that reduce their sensitivity to targeted therapy. Therefore, strategies directed at inhibiting two or more kinases are required to robustly block the growth of refractory tumour...
Autores principales: | Rao, Suman, Larroque-Lombard, Anne-Laure, Peyrard, Lisa, Thauvin, Cédric, Rachid, Zakaria, Williams, Christopher, Jean-Claude, Bertrand J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4414309/ https://www.ncbi.nlm.nih.gov/pubmed/25658745 http://dx.doi.org/10.1371/journal.pone.0117215 |
Ejemplares similares
-
Quantitative Analysis of the Potency of Equimolar Two-Drug Combinations and Combi-Molecules Involving Kinase Inhibitors In Vitro: The Concept of Balanced Targeting
por: Rao, Suman, et al.
Publicado: (2021) -
Molecular Analysis of the Superior Efficacy of a Dual Epidermal Growth Factor Receptor (EGFR)-DNA-Targeting Combi-Molecule in Comparison with Its Putative Prodrugs 6-Mono-Alkylamino- and 6,6-Dialkylaminoquinazoline in a Human Osteosarcoma Xenograft Model
por: Facchin, Caterina, et al.
Publicado: (2023) -
Design and Mechanism of Action of a New Prototype of Combi-Molecule “Programed” to Release Bioactive Species at a pH Range Akin to That of the Tumor Microenvironment
por: Larroque-Lombard, Anne-Laure, et al.
Publicado: (2021) -
Consultor Combi visual
Publicado: (1992) -
Consultor Combi visual
Publicado: (1988)